Document:

EX-10.16

 Exhibit 10.16 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 OMNIBUS
AMENDMENT AGREEMENT 
 THIS OMNIBUS AMENDMENT
AGREEMENT (“Agreement”) is entered into and made effective as of October 3, 2014 (the “Effective Date”) by and between ARIAD PHARMACEUTICALS,
INC., a Delaware corporation with its principal place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“ARIAD”), and BELLICUM PHARMACEUTICALS, INC., a
Delaware corporation with a place of business at 2130 Holcombe Boulevard, Suite 850, Houston, TX 77030 (“Bellicum”). ARIAD and Bellicum may be referred to herein individually as a “Party” and collectively as
“Parties.” 
 WHEREAS, the Parties previously executed the following agreements: an Amended
and Restated License Agreement, dated March 7, 2011 (the “License Agreement”); an Investor Rights Agreement, dated July 25, 2006, as amended on March 25, 2009 (the “IRA”); and a Stock Purchase
Agreement, dated July 25, 2006 (the “SPA”) (collectively, these three agreements are referred to herein as the “Current Agreements”); and 

WHEREAS, the Parties wish to restructure and amend the Current Agreements in accordance with the terms and conditions
set forth herein, it being understood that certain provisions in the License Agreement are not being amended but may no longer be applicable. 

NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

1. DEFINED TERMS. 

1.1 Any capitalized term used but not defined herein shall have the meaning ascribed to it under the Current Agreements. 

2. PROMISSORY NOTE. 

2.1 Payments by Bellicum. Bellicum will pay ARIAD Fifty Million US dollars ($50,000,000) in up to three installments pursuant to this
Agreement and a promissory note that will be executed by the Parties contemporaneously with this Agreement (the “Note”). 

(a) The first payment by Bellicum, in the amount of Fifteen Million US dollars ($15,000,000); the “First Payment”)
shall be delivered to ARIAD on the Effective Date following execution of this Agreement. 
 (b) The second payment by Bellicum, in the
amount of Twenty Million US dollars ($20,000,000; the “Second Payment”), is due on June 30, 2015. 
 (c) The
third payment by Bellicum, in the amount of Fifteen Million US dollars ($15,000,000; the “Third Payment”), is due on June 30, 2016. 

(d) Although specific due dates are recited in subsections (b) and (c) of this Section 2.1, Bellicum may prepay the
Second Payment and/or the Third Payment at any time following the First Payment and prior to the applicable due date. 

  
 1. 

 CONFIDENTIAL EXECUTION VERSION 

 

 2.2 Bellicum’s Other Obligations; Termination of the Note; Termination of this
Agreement. Bellicum’s obligations for the Second Payment and the Third Payment under the Note are absolute and unconditional, and such obligations of Bellicum are not affected by the expiration or termination of the Current Agreements (or
any of them) and/or this Agreement, for any reason other than the termination of both the License Agreement by Bellicum in accordance with Section 9.2 of the License Agreement and this Agreement by Bellicum in accordance with the
penultimate sentence of this Section 2.2 for an uncured material breach by ARIAD of at least one of the specific provisions of the License Agreement as listed and described in Exhibit B (attached hereto and incorporated herein;
each a “Section 2.2 Material Breach”), wherein each such Section 2.2 Material Breach, if uncured, would constitute grounds for termination of the License Agreement by Bellicum under Section 9.2 of the License Agreement. In
the event of an uncured Section 2.2 Material Breach, the Note will terminate upon delivery of written notice of termination by Bellicum to ARIAD referencing this Section 2.2, and thereafter the Note will have no further force or effect. In
addition to automatic termination of this Agreement as set forth in Section 3.2(d) hereof, each of Bellicum and ARIAD, as applicable, has the right to terminate this Agreement solely in the event such Party terminates the License Agreement in
accordance with Section 9.2.1 of the License Agreement based on an uncured material breach of the License Agreement by the other Party that would constitute grounds for termination under Section 9.2 of the License Agreement. For clarity,
in the event of termination in accordance with Section 9.2.1 of the License Agreement, Section 9.3 of the License Agreement (as amended hereby) shall apply. 

3. AMENDMENTS TO THE CURRENT AGREEMENTS. 

3.1 Upon First Payment. From and after the date of ARIAD’s receipt of the First Payment on the Effective Date: 

(a) Each of the defined terms Dimerizer, Licensed Field, Licensed Patent Rights, Licensed Product and [...***...] Analog, as set forth
in the License Agreement, is hereby deleted and replaced in its entirety with the following, corresponding new defined terms: 

“Dimerizer” shall mean any molecule that induces the interaction or proximity of two or more proteins, modified to contain a
dimerizer-binding domain, resulting in the activation of specific signaling, gene transcription, or protein secretion events in cultured cells, whole animals or humans. 

“Licensed Field” shall mean the treatment or prevention of the progression or occurrence of any disease, disorder or condition
in humans, other than a treatment or prevention achieved through an administration within the Excluded Field. 
 “Licensed Patent
Rights” shall mean (a) all Patent Rights Controlled by ARIAD as of the Original Effective Date or during the Primary License Term, which are necessary or useful for the development, manufacture, use, sale, offer for sale or import of
Licensed Products or of Dimerizers used or incorporated in Licensed Products, including without limitation Patent Rights covering the [...***...]-ARIAD MTA Technologies and (b) all Patent Rights whether or not controlled by ARIAD that are
listed on Schedule A1 (“Homodimerizer Patent Rights”) and Schedule 

  
 ***Confidential
Treatment Requested 
 2. 

 CONFIDENTIAL EXECUTION VERSION 

 

 A2 (“Heterodimerizer Patent Rights”), attached hereto and made a part
hereof, regardless of the ownership of such Patent Rights. Schedule A3 sets forth Patent Rights under the [...***...]-ARIAD MTA Technologies. Schedules A1, A2 and A3 shall be updated, as necessary, from time to time by ARIAD by written notice to
Bellicum. 
 “Licensed Product” shall mean any prophylactic or therapeutic product the manufacture, sale, import,
administration, activation or other use of which is covered by a claim of any Licensed Patent Rights or by Licensed Technology (including, without limitation, Patent Rights licensed or assigned to Bellicum that cover any of the [...***...]-ARIAD MTA
Technologies), and that (a) contains proteins or genes encoding proteins, the interaction or proximity of which proteins is induced by a Homodimerizer; (b) is a Homodimerizer for use with a product described in clause (a); or (c) is a
treatment regimen or process utilizing any product described in clause (a) or (b). The definition of Licensed Product expressly includes those products that are within the definition of Licensed Product on or prior to the effective date of the
Omnibus Amendment. For clarity, the term “Licensed Product,” as amended by the Omnibus Amendment, shall have the foregoing meaning until such time as the Third Payment (as defined in the Omnibus Amendment) has been made pursuant to the
terms of the Omnibus Amendment, and the term “Licensed Product” shall have the meaning set forth in Section 3.3(a) of the Omnibus Amendment after the Third Payment has been made pursuant to the terms of the Omnibus Amendment. 

“[...***...] Analog” shall mean a compound similar to [...***...] in [...***...]. 

and each of the following new defined terms (Academic MTA, Excluded Field, Heterodimerizer, Homodimerizer, Human Gene Therapy, MTA Technology
and Omnibus Amendment) is hereby inserted into Section 1 of the License Agreement in the appropriate alphabetical location: 

“Academic MTA” shall mean a material transfer agreement pursuant to which ARIAD provided a dimerizer or one or more genetic
constructs encoding a dimerizer binding protein to a researcher at an academic institution or at a not-for-profit entity. 

“Excluded Field” shall mean (1) Human Gene Therapy and (2) regulation of the expression of proteins or other
macromolecules [...***...]. 
 “Heterodimerizer” shall mean a Dimerizer that contains two structurally and functionally
distinct binding motifs, and that induces the interaction or proximity of proteins containing structurally and functionally different dimerizer-binding domains. By way of non-limiting example, [...***...] Analogs are Heterodimerizers. 

  
 ***Confidential
Treatment Requested 
 3. 

 CONFIDENTIAL EXECUTION VERSION 

 

 “Homodimerizer” shall mean a Dimerizer that contains two structurally and
functionally identical binding motifs, and that induces the interaction or proximity of proteins containing functionally identical dimerizer-binding domains. By way of non-limiting example, [...***...] is a Homodimerizer. 

“Human Gene Therapy” shall mean the in vivo administration of genetic material directly into a human being using viral
vectors, including but not limited to AAV Vectors, to transfer such material into the patient’s own cells for the purpose of producing proteins or other macromolecules that are expressed in or secreted from the transduced cells for therapeutic
or prophylactic purposes, where (i) the expression of such proteins or other macromolecules is regulated through the administration of [...***...] or another [...***...] Dimerizer, or (ii) the inserted genetic material is not regulated
through the administration of a Dimerizer. For clarity, “Human Gene Therapy” shall not include (a) any use where genetic material is inserted into a cell ex vivo, including without limitation any use for a cancer or non-cancer vaccine
or immunotherapeutic product or (b) any use where activation of genetic material for any function other than expression is regulated through the administration of Dimerizer. 

“MTA Technology” shall mean Homodimerizer and Heterodimerizer technology and related intellectual property rights related to
Licensed Products in the Licensed Field which have been licensed or otherwise conveyed to ARIAD under an Academic MTA and which ARIAD has the right to sublicense or otherwise convey to Bellicum hereunder. 

“Omnibus Amendment” shall mean the Omnibus Amendment Agreement, dated October 3, 2014, executed by the Parties. 

(b) Section 2.1.1 of the License Agreement is hereby deleted and replaced with the following: 

Grant of License. From and after the effective date of the Omnibus Amendment, ARIAD hereby grants to Bellicum an exclusive (even as to
ARIAD), fully-paid, irrevocable (unless this Agreement is terminated in accordance with the terms of the Omnibus Amendment) license, including the right to grant sublicenses in accordance with Section 2.1.4, under the Licensed Patent Rights and
Licensed Technology and ARIAD’s interest in any Improvements, subject at all times to the restrictions and obligations under the [...***...] Agreement with respect to the [...***...] IP, (a) to research, develop, test, obtain Regulatory
Approval for, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported Licensed Products (including, without limitation, any Dimerizer included or utilized therein) in the Territory, for any
and all uses within the Licensed Field during the Term, subject to the terms and conditions of this Agreement, and (b) to research, develop, test, make, have made, use, import and export, in each case solely for research purposes, including
pre-clinical IND-enabling toxicology and other pre-clinical studies (but not to conduct clinical 

  
 ***Confidential
Treatment Requested 
 4. 

 CONFIDENTIAL EXECUTION VERSION 

 

 trials with respect to or to obtain Regulatory Approval for, sell or commercialize), a
product that uses or incorporates a Heterodimerizer in the Licensed Field. For clarity, from and after the Effective Date, the term “Licensed Technology” includes MTA Technology relevant to Homodimerizers in the Licensed Field. From and
after the effective date of the Omnibus Amendment, the term “Licensed Technology” includes MTA Technology relevant to Heterodimerizers in the Licensed Field. 

(c) Section 2.1.4 of the License Agreement is hereby deleted and replaced with the following: 

Right to Sublicense and Subcontract. Bellicum shall have the right to grant sublicenses to any Affiliate and/or Sublicensee to all or any
portion of its rights under the license granted pursuant to Section 2.1.1; provided, however, that (a) such sublicense under the license granted pursuant to Section 2.1.1 shall be granted in connection with a license to all Patent
Rights and Technology Controlled by Bellicum, which are necessary or useful in the manufacture, use or sale of the Licensed Product(s) covered by the sublicense, (b) no sublicense may include a right to further sublicense any [...***...] IP
unless [...***...] has provided prior written consent to Bellicum and ARIAD allowing such further sublicense (and, if requested by Bellicum, ARIAD will assist Bellicum in obtaining such consent from [...***...]), and all such sublicenses of
[...***...] IP shall be subject and subordinate to, and consistent with, the terms and conditions of the [...***...] Agreement with respect to sublicenses of [...***...] IP, (c) ARIAD shall be notified of the grant of a sublicense to any and
all potential sublicenses, (d) any and all sublicenses shall be subject to, and consistent with, the terms and conditions of this Agreement, (e) upon termination of this Agreement, any such sublicense shall be considered a fully-paid,
direct license from ARIAD, as provided in Section 9.3 as amended hereby, and (f) Bellicum shall provide ARIAD with a copy of each such sublicense agreement (from which Bellicum may redact confidential terms that are not necessary to
disclose to ARIAD for purposes of confirming compliance with this Agreement and the [...***...] Agreement) within thirty (30) days of execution. In addition, Bellicum shall have the right to subcontract with any Third Party, including
[...***...], to have such Third Party perform work on Bellicum’s behalf pursuant to the license granted pursuant to Section 2.1.1 on terms which are subject to, and consistent with, the terms and conditions of this Agreement. ARIAD
acknowledges and agrees that, after the effective date of the Omnibus Amendment, Bellicum has no obligation to ARIAD to collect payments from its current or future sublicensees in respect of any sublicense of the rights granted to Bellicum under
this Agreement. 
 (d) Section 2.1.2 is hereby deleted from the License Agreement and replaced with the words “This section
intentionally omitted.” All other provisions of Section 2.1 of the License Agreement (Sections 2.1.3 and 2.1.5 through 2.1.9) remain unchanged and in full force and effect. 

  
 ***Confidential
Treatment Requested 
 5. 

 CONFIDENTIAL EXECUTION VERSION 

 

 (e) Bellicum’s obligation to develop and commercialize certain Licensed Products
in the Licensed Field, as set forth in Section 3.2 of the License Agreement, will continue until ARIAD’s parallel obligation to [...***...] terminates upon the expiry of the patents as set forth in the agreement between ARIAD and
[...***...]. Upon the date of termination of such parallel obligation of ARIAD, all of Bellicum’s obligations under Section 3.2 of the License Agreement are automatically terminated. 

(f) Section 3.4 of the License Agreement is amended by adding the following sentence at the end thereof: “For clarity, ARIAD
retains the right to manufacture or have manufactured any Dimerizer other than [...***...] for use outside the Licensed Field, and to grant licenses to Third Parties to do so, subject to ARIAD’s compliance with Section 2.2.1(a).” 

(g) All other provisions of Article 3 of the License Agreement (Sections 3.1, 3.3 and 3.5) remain unchanged and in full force and
effect. 
 (h) With the exception of Section 4.1.4 (which continues in full force and effect), Sections 4.1 through 4.3 of the
License Agreement have no further force and effect and are deleted from the License Agreement. Each such deleted section is hereby replaced with the words: “This section intentionally omitted.” 

(i) Under Section 6.1 of the License Agreement, ARIAD will continue to have the sole right, but not the obligation, to prepare,
file, prosecute, obtain and maintain the Licensed Patent Rights, other than the Licensed Patent Rights covering the [...***...]-ARIAD MTA Technologies, which are currently being prepared, filed, prosecuted, obtained and maintained by Bellicum
pursuant to ARIAD’s delegation of such responsibility to Bellicum. ARIAD will give good faith consideration to Bellicum’s requests and input regarding such activities in connection with the Licensed Patent Rights, and will not discontinue
such activities or materially diminish the scope of claims within any Licensed Patent Rights without prior written notice to Bellicum and good faith consideration of Bellicum’s interests and comments. If ARIAD wishes to discontinue payments for
maintenance of any patent within the Licensed Patent Rights, ARIAD hereby grants to Bellicum the right to make such maintenance payments for such patent. Notwithstanding anything to the contrary in Section 6.1 of the License Agreement, the
following will apply from and after the Effective Date: In relation to Section 6.1 of the License Agreement, ARIAD will continue to have the first right to enforce any Licensed Patent Rights, provided, however that (1) if ARIAD elects not
to enforce any of the Licensed Patent Rights owned by ARIAD against alleged infringement by the manufacture, use, sale or import by a Third Party(ies) (as defined in the License Agreement) of a product within the definition of “Licensed
Product” in the Licensed Field, Bellicum may do so at its sole expense without any further consent required from ARIAD; and (2) if ARIAD elects not to enforce any of the Licensed Patent Rights licensed by ARIAD from a Third Party(ies)
against alleged infringement by the manufacture, use, sale or import by a Third Party(ies) of a product within the definition of “Licensed Product” in the Licensed Field, then to the full extent that ARIAD may do so under its license
agreement with such Third Party(ies), but subject to any right of such Third Party(ies) to enforce such Licensed Patent Rights, ARIAD will delegate to Bellicum the right to enforce such Licensed Patent Rights at Bellicum’s sole expense;
provided that, if such consent is required under any license agreement from a Third Party(ies), ARIAD will use good faith efforts to obtain consent to delegate such enforcement right to Bellicum; and further provided that, if the Third

  
 ***Confidential
Treatment Requested 
 6. 

 CONFIDENTIAL EXECUTION VERSION 

 

 
Party licensor agrees that ARIAD may enforce such Licensed Patent Rights on behalf of Bellicum, but will not consent to delegation of such enforcement right to Bellicum, then ARIAD will exercise
its enforcement right on behalf of Bellicum, at Bellicum’s direction and expense. In addition, any filing, prosecution and/or maintenance rights, and any enforcement rights, that ARIAD possesses under an Academic MTA shall be treated in the
same manner as Licensed Patent Rights described in Section 6.1 of the License Agreement (as modified by this Section 3.1(i)). 

(j) Section 9.3 of the License Agreement is hereby amended by deleting clause (a) (ii) thereof and by deleting from
clause (b) the words “with royalties to be paid to ARIAD on all Net Sales of such Licensed Products as provided for in this Agreement.” 

(k) ARIAD will not sell, transfer, pledge or otherwise dispose of any shares of Bellicum Common Stock, unless (i) Bellicum has
completed a registered public offering of its Common Stock (an “IPO”) at any time and has not made the Second Payment by October 31, 2015 (including applicable interest commencing July 1, 2015 as set forth in
Section 3.2(b) of this Agreement); or (ii) each of the License Agreement and this Agreement has been terminated. 
 (l)
ARIAD will not modify the [...***...] Agreement or the [...***...] Agreement in any manner, and will not take or fail to take any actions that would diminish Bellicum’s rights or increase Bellicum’s obligations under those agreements.
Notwithstanding anything to the contrary in the License Agreement, ARIAD will be solely responsible for paying, and shall pay, any and all royalties, milestone payments and other payments owed under the [...***...] Agreement as a result of Net Sales
or milestone achievements by Bellicum, its Affiliates or Sublicensees. If the [...***...] Agreement is terminated (as described in Section 2.1.9 of the License Agreement), ARIAD will remain responsible for making any payments to [...***...]
that are owed as a result of Bellicum’s activities as a direct licensee of [...***...]. 
 (m) Bellicum recognizes that ARIAD has
executed numerous Academic MTAs, pursuant to many of which ARIAD has obtained certain non-exclusive rights which may be useful to Bellicum in the practice of the licenses granted to Bellicum under the License Agreement (as amended by this
Agreement). ARIAD has provided to Bellicum before the Effective Date a listing of such Academic MTAs which ARIAD believes (but does not represent) is complete. To the extent necessary and permitted by any Academic MTA, ARIAD consents to Bellicum
contacting the researcher or his or her institution or entity under such Academic MTA to discuss or seek rights to the intellectual property rights resulting from the research conducted thereunder. Subject to any confidentiality obligation under any
Academic MTA, ARIAD will notify Bellicum in writing of the existence of patents and patent applications relevant to the research, development, testing, manufacture, use, sale or import of Licensed Products in the Licensed Field, and disclosed to
ARIAD in connection with such Academic MTAs. If ARIAD has a right to negotiate for any option or license rights to such patents and patent applications, then at Bellicum’s written request, ARIAD will reasonably cooperate with Bellicum to seek
to obtain a right for Bellicum to negotiate for such option or license rights to such patents and patent applications; provided that if ARIAD has a right to convey such option or license rights to another party, but is unable to obtain such
negotiation right for Bellicum after good faith efforts, then if the other party to the Academic MTA agrees that ARIAD may negotiate such option of license rights on behalf of Bellicum, but will not consent to delegation of such negotiation right

  
 ***Confidential
Treatment Requested 
 7. 

 CONFIDENTIAL EXECUTION VERSION 

 

 
to Bellicum, ARIAD will cooperate with Bellicum in negotiating such option or license rights on behalf of Bellicum, and convey to Bellicum the negotiated rights, all at Bellicum’s sole
expense. If Bellicum believes that a researcher, or his or her institution or entity, is not complying with his/her Academic MTA, ARIAD and Bellicum will cooperate to ensure that such researcher is in compliance. 

3.2 Upon Second Payment. From and after the date of ARIAD’s receipt of the Second Payment (together with any applicable interest
payable pursuant to subsection (b) below) (“Second Payment Date”): 
 (a) ARIAD will surrender to
Bellicum all shares of Bellicum Common Stock held by ARIAD as of the Second Payment Date, provided that the Second Payment Date is no later than December 31, 2015, and concurrently with such surrender of shares, each of the SPA and IRA will
terminate and have no further force or effect (unless the SPA and/or the IRA has/have previously terminated in accordance with its/their respective terms). 

(b) If the Second Payment is not delivered by Bellicum on or before June 30, 2015, then, from July 1, 2015 until such time as
the Second Payment, plus interest from July 1, 2015 (at the rate of ten percent (10%) per annum or the maximum rate allowed by applicable law, if lower), is paid in full: (i) ARIAD will not surrender the Bellicum Common Stock held by
ARIAD; (ii) each of the SPA and IRA will continue in full force and effect, unless terminated upon an IPO in accordance with their respective terms; (iii) under Section 2.1.4 of the License Agreement, any right of Bellicum to grant
sublicenses without ARIAD’s consent will be suspended until the Second Payment is delivered; (iv) Bellicum shall pay ARIAD, from an escrow account held by an independent third party to be established at the time of the first receipt of
Cash Consideration (defined below) to provide funds for such payment, (A) on July 1, 2015, fifty percent (50%) of any cash consideration received by Bellicum under sublicense agreements and directly related contemporaneous agreements
executed by Bellicum with such sublicensees (“Cash Consideration”) subsequent to August 22, 2014 and prior to July 1, 2015; provided that the following are expressly excluded from such Cash Consideration described in this
Section 3.2(b) and in Section 3.3(b) below: amounts received by Bellicum (1) in arrears and based on reported expenditures of time and materials for the performance of bona fide product development work or research work, (2) for
equity (including, convertible equity, such as warrants and convertible debt) at fair market value, and (3) in arrears and based on reported expenditures for patent expenses incurred by Bellicum; and (B) one hundred percent (100%) of
any milestone payments that would have been owed by Bellicum to ARIAD under the License Agreement as it existed prior to the Effective Date, if the corresponding milestone event is achieved subsequent to the Effective Date of this Agreement and
prior to the Second Payment Date. 
 (c) For avoidance of doubt, Bellicum’s failure to deliver the Second Payment on or before
June 30, 2015 does not give ARIAD the right to terminate the License Agreement in response to such failure. 
 (d) If the Second
Payment is not delivered by Bellicum on or before June 30, 2016, ARIAD will have the right, in its sole discretion, to terminate the License Agreement in its entirety upon delivery to Bellicum of written notice of termination that makes
reference to this Section 3.2(d). In the event of such termination, this Agreement shall be terminated automatically. For clarity, termination of this Agreement pursuant to this Section 3.2(d) shall not terminate the Note, which shall
continue in full force and effect. 

  
 8. 

 CONFIDENTIAL EXECUTION VERSION 

 

 3.3 Upon Third Payment. From and after the date of ARIAD’s receipt of the Third
Payment (together with any applicable interest payable pursuant to subsection (b) below) (“Third Payment Date”): 

(a) If the Third Payment is delivered by Bellicum on or before June 30, 2016, the defined term Licensed Product will be further
amended and expanded in scope to the extent permitted by ARIAD’s pre-existing obligations and agreements, as follows: 

“Licensed Product” shall mean any prophylactic or therapeutic product the manufacture, sale, import, administration,
activation or other use of which is covered by a claim of any Licensed Patent Rights or by Licensed Technology (including, without limitation, Patent Rights licensed or assigned to Bellicum that cover any of the [...***...]-ARIAD MTA Technologies)
and that (a) contains proteins or genes encoding proteins, the interaction or proximity of which proteins is induced by either a Homodimerizer or a Heterodimerizer; (b) is a Homodimerizer or Heterodimerizer for use with a product described
in clause (a); or (c) is a treatment regimen or process utilizing any product described in clause (a) or (b). For clarity, this definition of Licensed Product expressly includes those products that are within the definition of Licensed
Product as of the effective date of the Omnibus Amendment. 
 (b) If the Third Payment is not delivered by
Bellicum on or before June 30, 2016, then from July 1, 2016 until such time as the Third Payment, plus interest from July 1, 2016 (at the rate of ten percent (10%) per annum or the maximum rate allowed by applicable law, if
lower), is paid in full: (i) under Section 2.1.4 of the License Agreement, any right of Bellicum to grant sublicenses without ARIAD’s consent will be suspended until the Third Payment is delivered; (ii) Bellicum shall pay ARIAD,
from an escrow account to be established to provide funds for such payment, (A) on July 1, 2016, fifty percent (50%) of any Cash Consideration received by Bellicum subsequent to the date of the Second Payment and prior to July 1,
2016 (excluding amounts paid to ARIAD pursuant to Section 3.2(b)(iv)(A) above), and (B) one hundred percent (100%) of any milestone payments that would have been owed by Bellicum to ARIAD under the License Agreement as it existed
prior to the effective date of the Omnibus Amendment, if the corresponding milestone event is achieved subsequent to the Second Payment Date and prior to the Third Payment Date (excluding amounts paid to ARIAD pursuant to Section 3.2(b)(iv)(B)
above). 
 (c) During any period in which the Second Payment or the Third Payment, as applicable, remains unpaid past its due date,
fifty percent (50%) of any funds raised by Bellicum in any private equity or debt financing for capital raising purposes (i.e., not including bank line-of-credit or equipment financings) (“Raised Capital”) will be applied
against such past due, unpaid amount. If all of the Second Payment and Third Payment have not been delivered by Bellicum on or before June 30, 2017, ARIAD will have the right, in its sole discretion, to terminate the License Agreement, upon
delivery to Bellicum of written notice of termination that makes reference to this Section 3.3(c). In the event of such termination, this Agreement shall be terminated automatically. 

  
 ***Confidential
Treatment Requested 
 9. 

 CONFIDENTIAL EXECUTION VERSION 

 

 (d) Bellicum shall maintain and keep, until the Third Payment has been delivered to
ARIAD, complete and accurate records of (i) all Cash Consideration received by Bellicum as set forth in Sections 3.2(b)(iv)(A) and 3.3(b)(ii)(A), (ii) all Raised Capital as set forth in Section 3.3(c) and (iii) achievement of
milestone events as set forth in Sections 3.2(b)(iv)(B) and 3.3(b)(ii)(B). Subject to the other terms of this Section 3.3(d), at the request of ARIAD, which request shall not be made more than once per calendar year during the Term, then upon
at least thirty (30) days’ prior written notice from ARIAD, and at the expense of ARIAD (except as otherwise provided herein), Bellicum shall permit an independent certified public accountant reasonably selected by ARIAD and reasonably
acceptable to Bellicum to inspect (during regular business hours) the relevant records required to be maintained by Bellicum under this Section 3.3(d) (provided no records may be reviewed more than once under this Section 3.3(d)). Results
of such inspection shall be binding on both Parties absent manifest error. ARIAD shall treat the results of any such accountant’s review of records under this Section 3.3(d) as Confidential Information of Bellicum subject to the terms of
Section 5.1 of the License Agreement. If any such inspection reveals a deficiency in the calculation of amounts deposited in the escrow account and/or payment by Bellicum required by Section 3.2(b)(iv) or 3.3(b)(ii), then Bellicum shall
promptly add such deficiency to the escrow account or pay ARIAD the amount remaining to be paid. 
 4. BELLICUM COMPANY
SALE AND PUBLIC OFFERINGS. 
 4.1 Payment Due Date Modification in the
Event of Company Sale or Certain Registered Public Offerings. In the event of a Company Sale (as defined in the SPA) of Bellicum, any remaining balance of the Second Payment and the Third Payment that has not been paid shall become due and
payable at the closing of the Company Sale. In the event Bellicum raises (a) Seventy-Five Million US dollars ($75,000,000) or more in one or more registered public offerings (a “Public Offering”) on or before
March 31, 2015, or (b) One Hundred Million US dollars ($100,000,000) or more in one or more Public Offerings subsequent to March 31, 2015, then, the Third Payment will become due and payable on the date that is the earlier of
(x) nine (9) months after the closing of the Public Offering that brings the aggregate proceeds received by Bellicum (before expenses, discounts and commissions and other deductions from the gross amount of the Public Offering
(“Gross Proceeds”)) to at least $75 million or $100 million, as applicable; or (y) in the event of a Public Offering resulting in aggregate Gross Proceeds received by Bellicum of at least $100 Million,
December 31, 2015. Notwithstanding the foregoing, if Bellicum completes an IPO and a secondary Public Offering that alone or together raise aggregate Gross Proceeds of at least One Hundred Twenty-Five Million US dollars ($125,000,000), the
Third Payment shall become due and payable within five (5) days of the closing of the IPO or secondary Public Offering that results in aggregate Gross Proceeds received by Bellicum of at least One Hundred Twenty-Five Million US dollars
($125,000,000). In no event shall the Third Payment be due later than June 30, 2016. 

  
 10. 

 CONFIDENTIAL EXECUTION VERSION 

 

 5. Construction of Agreement. 

5.1 Entire Agreement. (a) This Agreement shall be effective for all purposes as of the Effective Date. To the extent that there are
any inconsistencies between the express provisions of this Agreement and any of the Current Agreements, the terms of this Agreement shall supersede those set forth in the Current Agreements. Except as expressly modified by this Agreement, each of
the Current Agreements shall remain in full force and effect in accordance with its terms. As of the Effective Date, the term “Agreement” as used in the Current Agreements shall mean the Current Agreements as amended by this Agreement.
(b) This Agreement, together with the Current Agreements, as amended hereby, constitutes the entire agreement between the Parties with respect to the subject matter of the Current Agreements and this Agreement. No modification shall be
effective unless in writing with specific reference to this Agreement and signed by the Parties. (c) The terms of this Agreement are hereby deemed confidential information of each Party, and this confidential information shall be treated in the
same manner under this Agreement as “Confidential Information” is treated under the License Agreement; provided, however, that subject to the following sentence, the Parties intend to issue a joint press release upon full execution of this
Agreement, and thereafter either Party may issue a press release upon delivery of the Second Payment and the Third Payment, and in the event of termination of this Agreement. Each Party shall provide any proposed press release in connection with
this Agreement, the Second Payment or the Third Payment to the other Party at least five (5) days prior to issuing such proposed press release, and shall give good faith consideration to comments from the other Party. 

5.2 Disputes. In the event of the occurrence of a dispute as to either Party’s rights and/or obligations hereunder, the resolution
of the dispute will be governed by Article 10 of the License Agreement.  
 5.3 Governing Law. This Agreement will be
construed, interpreted and applied in accordance with the laws of the State of New York (excluding its body of law controlling conflicts of law). 

5.4 Counterparts. This Agreement may be executed in any number of counterparts by original, facsimile or PDF signature, each of which
shall be deemed an original, and all of which together shall constitute one and the same instrument, binding on the Parties notwithstanding that each of the Parties may have signed different counterparts. 

5.5 Waiver. The terms or conditions of this Agreement may be waived only by a written instrument executed by Bellicum and ARIAD. The
failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a continuing
waiver of such condition or term or of another condition or term. 
 5.6 Assignment. Neither this Agreement nor any right or
obligation hereunder may be assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior written consent of the other Party; provided, however, that either Party may, without the written consent of the other,
assign this Agreement and its rights and delegate its obligations to its Affiliates or in connection with the transfer or sale of all or substantially all of such Party’s 

  
 11. 

 CONFIDENTIAL EXECUTION VERSION 

 

 
assets or business related to this Agreement, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of its
assignor under this Agreement. Any purported assignment in violation of this Section 5.5 shall be void. The terms and conditions of this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the
Parties. 
 6. Hedging Transactions. 

6.1 Until such time as all payments due hereunder or under the Note have been made by Bellicum to ARIAD, Bellicum will not engage in any
Hedging Transaction with Comerica Bank, any affiliate of Comerica Bank, or any successor in interest to the rights of Comerica Bank under the Subordination Agreement dated October 3, 2014 by and among Comerica Bank, ARIAD and Bellicum. As used
herein, “Hedging Transaction” means any interest rate swap transaction, basis swap transaction, forward rate transaction, equity transaction, equity index transaction, foreign exchange transaction, cap transaction, floor transaction
(including any option with respect to any of these transactions and any combination of any of the foregoing). 
 Signature page
follows. 

  
 12. 

 CONFIDENTIAL EXECUTION VERSION 

 

 IN WITNESS WHEREOF, the Parties hereto
have caused their duly authorized representatives to execute this Omnibus Amendment Agreement as of the Effective Date. 
  

									
	 ARIAD PHARMACEUTICALS, INC.
  

/s/ Hugh M. Cole
	 		 	 BELLICUM PHARMACEUTICALS, INC.
  

/s/ Thomas J. Farrell

	(signature)	 		 	(signature)
					
	By:	 	Hugh M. Cole	 		 	By:	 	Thomas J. Farrell
		 	(print or type name)	 		 		 	(print or type name)
					
	Title:	 	 Chief Business Officer
	 		 	Title:	 	 President and CEO

	  
 Date:
	 	 October 3, 2014
	 		 	  
 Date:
	 	 October 3, 2014

  

  

 CONFIDENTIAL EXECUTION VERSION 

 

 Schedule A1 

Homodimerizer Patent Rights 
 Technologies Other
Than [...***...]-ARIAD MTA Technologies 
  

							
	 	 	 	 
	 Title

 
	  	 Country   

 
	  	 Serial No.

 
	  	 Patent No.

 

	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]            
	 [...***...]
	  	[...***...]	  	[...***...]	  	 
	 	  	 [...***...]    

 
	  	 [...***...]            

 
	  	 

  
 ***Confidential
Treatment Requested 

 CONFIDENTIAL EXECUTION VERSION 

 

 Schedule A2 

Heterodimerizer Patent Rights 
 Technologies
Other Than [...***...]-ARIAD MTA Technologies 

  
 ***Confidential
Treatment Requested 

 CONFIDENTIAL EXECUTION VERSION 

 

									
	 	 	 	 	 
	 Title

 
	  	 Country

 
	  	 Serial No.

 
	  	 Patent No.

 
	  	 Issued

 

	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	
[...***...]
	  	[...***...]     	  	[...***...]          	  	[...***...]            	  	[...***...]     

  
 ***Confidential
Treatment Requested 
 3. 

 CONFIDENTIAL EXECUTION VERSION 

 

 Schedule A3 

[...***...]-ARIAD MTA Technologies 
  

									
	 	 	 	 	 
	Country    	  	 Publication  

No.  
  
	  	Serial No.  	  	Title    	  	
Patent
 No.

	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	 	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	 
	 [...***...]
	  	[...***...]	  	[...***...]                	  	[...***...]	  	 
	 [...***...]
	  	[...***...]                	  	[...***...]	  	[...***...]	  	[...***...]    
	 [...***...]    
	  	 	  	[...***...]	  	[...***...]	  	 

  
 ***Confidential
Treatment Requested 
  

 CONFIDENTIAL EXECUTION VERSION 

 

 Exhibit B 

Section 2.2 Material Breaches 

Section 2.1.1 — any act or omission by ARIAD that is inconsistent with, or that materially adversely affects, the rights and licenses granted to
Bellicum as set forth in Section 2.1.1; 
 Section 2.1.3(a) – any act by ARIAD that is inconsistent with the prohibitions imposed on ARIAD
pursuant to Section 2.1.3(a), including, but not limited to, any such act that materially adversely changes any such prohibition, or that to any extent releases ARIAD from any such prohibition; 

Section 2.1.4 — any act or omission by ARIAD that is inconsistent with, or that materially adversely affects, Bellicum’s right to grant
sublicenses and to subcontract with Third Parties, as set forth in Section 2.1.4, including, but not limited to, any act or omission whereby ARIAD fails to take steps to assist Bellicum in obtaining consent from [...***...], as set forth in
clause (b) of Section 2.1.4; 
 Section 2.1.5 – any willful or intentional material breach of ARIAD’s obligation to disclose all
Licensed Patent Rights and Licensed Technology as set forth in Section 2.1.5; 
 Section 2.1.6 – any act or omission by ARIAD that materially
adversely affects Bellicum’s right to receive, or Bellicum’s receipt of, ARIAD Regulatory Information as set forth in Section 2.1.6; 

Section 2.2.1(a) – any act by ARIAD that constitutes a material breach of Section 2.2.1(a) solely due to (i) the practice by ARIAD of any
Bellicum Patent Rights, Bellicum Technology or Bellicum’s interest in any Improvements, or (ii) the grant by ARIAD to a Third Party of a sublicense to practice Bellicum Patent Rights, Bellicum Technology and or Bellicum’s interest in
any Improvements, in either case (i) or (ii) to develop, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export or have exported ARIAD Products in the Licensed Field; 

Section 4.1.4 – any willful or intentional material breach of ARIAD’s royalty payment obligation set forth in the first sentence of
Section 4.1.4; 
 Sections 5.1, 5.2 and 5.3 – any material breach of ARIAD’s confidentiality obligations owed to Bellicum that materially
adversely affects the Licensed Patent Rights licensed to Bellicum by ARIAD; and 
 Section 6 — any act or omission by ARIAD that constitutes a
material breach of ARIAD’s obligations under Section 6.1, and where such material breach materially adversely affects the Licensed Patent Rights licensed to Bellicum by ARIAD 

  
 ***Confidential
Treatment Requested 
 2.EX-10.17

 Exhibit 10.17 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 EXCLUSIVE
LICENSE AGREEMENT 
 BAYLOR COLLEGE OF MEDICINE 

BELLICUM PHARMACEUTICALS, INC. 
  

	RE:	1. OTA # 01.085, entitled “Induced CD40 Activation in Dendritic Cell-based Prostate Cancer Vaccines.” Developers: David M. Spencer, Kevin M. Slawin, Brent A. Hanks. 

2. BLG # 08-024, entitled, “Development of an Improved, Inducible CD-40 — “iCD40 Turbo.” Developer: David M.
Spencer. 
 This Exclusive License Agreement (hereinafter called “Agreement”), to be effective as of the     
day of March, 2008 (hereinafter called “Agreement Date”), is by and between Baylor College of Medicine (hereinafter called “BAYLOR”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza,
Houston, Texas 77030, and Bellicum Pharmaceuticals, Inc., a corporation organized under the laws of Delaware and having a principal place of business at Twelve Greenway Plaza, Suite 1380, Houston, TX 77046, and its Affiliates (hereinafter,
collectively referred to as “BELLICUM”), 
 WITNESSETH: 

WHEREAS, BAYLOR, by virtue of its relationship with its faculty, staff and students and conveyances with the Developers (as defined below) and
under and pursuant to the terms and provisions of its Policy on Inventions and Patents, is the owner of certain right, title and interest in and to the Subject Technology and Patent Rights (as defined below); and 

WHEREAS, BAYLOR granted certain rights in the Subject Technology and Patent Rights to David M. Spencer, Kevin M. Slawin and Brent A. Hanks by
the written release dated February 11, 2004 and by the Assignment from BAYLOR to assignees David M. Spencer, Kevin M. Slawin and Brent A. Hanks, dated April 6, 2004; and 

WHEREAS, BAYLOR granted certain rights in the Subject Technology and Patent Rights to [...***...] under the terms of the Material Transfer
Agreement between Baylor College of Medicine and [...***...], dated [...***...]; and 
 WHEREAS, BAYLOR is willing to grant a worldwide,
exclusive license to all of the right, title and interest owned by BAYLOR as of the Agreement Date in the Subject Technology and Patent Rights to BELLICUM on the terms set forth herein; and 

***Confidential Treatment Requested 

  
 - 1 - 

 NOW, THEREFORE, for and in consideration of the foregoing and rights and obligations hereafter,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto expressly agree as follows: 

1. DEFINITIONS AS USED HEREIN 
 1.1
“Affiliates” shall mean any corporation, partnership, joint venture or other entity of which the common stock or other equity ownership thereof is 50% or more owned by BELLICUM. 

1.2 “Common Stock” shall have the meaning given in Paragraph 4.1. 

1.3 “Confidential Information” shall mean any proprietary and secret ideas, proprietary technical information, know-how and
proprietary commercial information or other similar proprietary information. Neither Party shall have an obligation of confidentiality with respect to Confidential Information that: 

(i) at the time of its disclosure or thereafter is disclosed in a publicly available document through no fault of the receiving Party; 

(ii) at the time of its disclosure is, or thereafter becomes without fault of the receiving Party, part of the public domain; 

(iii) was in the possession of the receiving Party prior to disclosure by the disclosing Party hereunder and was not acquired directly or
indirectly from any third party under obligation of confidentiality to the disclosing Party; 
 (iv) subsequent to its disclosure, is
obtained from a third party not subject to a contractual or fiduciary obligation for confidentiality to the disclosing Party; or 
 (v) is
required by court or governmental order, law or regulation to be disclosed. 
 1.4 “Developers” shall mean David M. Spencer,
employee of BAYLOR, and Kevin M. Slawin and Brent A. Hanks, past employees of BAYLOR. 
 1.5 “Legal Costs” shall mean all legal
fees and expenses, filing or maintenance fees, assessments and all other costs and expenses related to prosecuting, obtaining and maintaining patent protection on the Patent Rights in the United States and foreign countries. 

1.6 “Licensed Method(s)” will mean any method the practice of which would constitute, but for the license granted to BELLICUM under
this Agreement, an infringement of any Valid Claim of the Patent Rights. 

  
 - 2 - 

 1.7 “Licensed Product(s)” will mean any product that the manufacture, use or sale of
which would constitute, but for the license granted to BELLICUM under this Agreement, an infringement of any Valid Claim of the Patent Rights. 

1.8 ‘Party” shall mean either BELLICUM or BAYLOR, and the “Parties” shall mean BELLICUM and BAYLOR. 

1.9 “Patent Rights” shall mean all right, title and interest owned by BAYLOR as of the Agreement Date in patent applications filed
before, on or after the Agreement Date, that pertain to the Subject Technology, including without limitation United States Patent Application No. 10/781,384 (entitled “Induced Activation in Dendritic Cells,” filed 02/18/2004),
European Patent Application No. 4712328.9, and Canadian Patent Application No. 2,516,320, the inventions described and claimed therein, and all other pending United States or foreign patent applications or parts thereof and any United
States or foreign patent which issues from any such patent applications, and any and all divisions, reissues, re-examinations, renewals, continuations, continuations-in-part to the extent the claims are directed to subject matter specifically
described in the aforementioned patent applications, and extensions thereof, and all other counterpart, pending or issued patents in all other countries. 

1.10 “Subject Technology” shall mean and include all right, title and interest owned by BAYLOR as of the Agreement Date in any
technology, biological materials, methods, documents, materials, tests, know-how and all confidential information existing as of the Agreement Date pertaining to the following technology disclosures (as listed in Appendix A): 

1. OTA # 01-085, entitled “Induced Activation in Dendritic Cell-based Prostate Cancer Vaccines.” Developers: David M. Spencer,
Kevin M. Slawin, Brent A. Hanks. 
 2. BLG # 08-024, entitled, “Development of an Improved, Inducible CD-40 — “iCD40
Turbo,” Developer: David M. Spencer. 
 1.11 “Valid Claim” means a claim of an issued unexpired patent within the Patent
Rights that has not been held unenforceable, unpatentable or invalid by a final decision of a court of competent jurisdiction or by a final decision of a patent office, and that has not been admitted to be invalid or unenforceable through reissue,
disclaimer or otherwise. 
 2. GRANT OF LICENSE 

2.1 Grant. Subject to the reservations of rights set forth in Paragraph 2.2, BAYLOR hereby grants to BELLICUM, and BELLICUM
hereby accepts, an exclusive, worldwide, sublicensable, fully paid-up license under the Patent Rights and Subject Technology, to make, have made, use, import, export, distribute, research, develop, obtain regulatory approval, manufacture, have
manufactured, offer for sale and sell Licensed Products and Licensed Methods. 

  
 - 3 - 

 2.2 Restrictions. The grant in Paragraph 2.1 shall be further subject to,
restricted by and non-exclusive with respect to: 
 (i) the making or use of the Subject Technology and Patent Rights by BAYLOR for
non-commercial research, patient care, teaching and other educationally related purposes; 
 (ii) any non-exclusive license of the Subject
Technology and/or Patent Rights that BAYLOR grants to other academic or research institutions for non-commercial research purposes; and 

(iii) any non exclusive license of the Subject Technology and/or Patent Rights that BAYLOR is required by law or regulation to grant to the
United States of America or to a foreign state pursuant to an existing or future treaty with the United States of America; and 
 (iv) the
non-exclusive, worldwide, paid-up license granted to [...***...] under the terms of the [...***...] between Baylor College of Medicine and [...***...], dated [...***...]. 

The grant in Paragraph 2.1 also is subject to BAYLOR’S grant of certain rights in the Subject Technology and Patent Rights to David M. Spencer, Kevin M.
Slawin and Brent A. Hanks by the written release dated February 11, 2004 and by the Assignment from BAYLOR to assignees David M. Spencer, Kevin M. Slawin and Brent A. Hanks, dated April 6, 2004. 

2.3 Government Reservation. Rights under this Agreement are subject to rights required to be granted to the Government of the
United States of America pursuant to 35 USC Section 200-212, including a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the subject inventions throughout the
world. 
 3. PAYMENTS 
 3.1
Common Stock. As full consideration for the rights conveyed by BAYLOR under this Agreement, BELLICUM shall issue to BAYLOR forty-thousand (40,000) shares of its common stock, $0.01 par value (the “Common Stock”), within
sixty (60) days after the Agreement Date. Such Common Stock shall be distributed as per Appendix A. 
 3.2 Legal
Costs. BELLICUM will be responsible for payment of all Legal Costs incurred after the Agreement Date, which BELLICUM will pay directly to each legal service provider on invoices for such legal costs received by BELLICUM. 

  
 ***Confidential
Treatment Requested 
 - 4 - 

 4. REPORTING 

4.1 Annual Reports. BELLICUM shall provide to BAYLOR a summary commercialization plan of research for each Licensed Product and
Licensed Method in clinical development [...***...] days after the commencement of clinical development of the first Licensed Product, and it will provide an activity report to BAYLOR on [...***...]. Information in the summary commercialization plan
and the activity reports is Confidential Information of BELLICUM. 
 4.2 Notification of Merger. In the event of acquisition,
merger, change of corporate name, or change of make-up, organization, or identity, BELLICUM shall notify BAYLOR in writing within [...***...] days of such event. 

5. TRANSFER OF SUBJECT TECHNOLOGY 

Upon receipt of the Common Stock described in Paragraph 3.1, BAYLOR shall, upon written request by BELLICUM, provide BELLICUM with reasonable
quantities of the Subject Technology. The Subject Technology shall be sent to such address and using such shipping method as may be specified by BELLICUM in the request. 

6. SUBLICENSES 
 All sublicenses
granted by BELLICUM of its rights hereunder shall be subject to the terms of this Agreement. BELLICUM shall be responsible for its sublicensees and shall not grant any rights which are inconsistent with the rights granted to and obligations of
BELLICUM hereunder. Should BELLICUM become aware of an act or omission of a sublicensee that would be a material breach of this Agreement, BELLICUM shall use reasonable business efforts to cause the sublicensee to cure the breach. No such sublicense
agreement shall contain a provision that illegally extends the term of Patent Rights under this Agreement. BELLICUM shall give BAYLOR prompt notification of the identity and address of each sublicensee with whom it concludes a sublicense agreement
and shall supply BAYLOR with a copy of each such sublicense agreement in which BELLICUM may redact financial information. 
 7. PATENTS AND
INFRINGEMENT 
 7.1 Patent Prosecution Responsibility. From the Agreement Date and for the term of this Agreement,
BELLICUM shall have primary responsibility, at its sole cost, to use patent counsel of its choice that is reasonably acceptable to BAYLOR for filing, prosecuting and maintaining all patent applications and patents included in the Patent Rights and
Subject Technology licensed hereunder, except that BAYLOR may assume responsibility at its sole expense for pursuing any protection which BELLICUM declines to prosecute pursuant to Paragraph 7.2 of this Agreement. 

  
 ***Confidential
Treatment Requested 
 - 5 - 

 7.2 Notification of Intent Not to Pursue. In the event that BELLICUM decides not to
pay for the costs associated with either: (i) the prosecution of patent applications in the Patent Rights or (ii) maintenance of any United States or foreign issued patent in the Patent Rights, BELLICUM shall provide BAYLOR [...***...]
days written notice thereof. BELLICUM’s right under this Agreement to practice an invention claimed in an issued patent not pursued under this Section 7.2 shall terminate [...***...] days of such notice in the jurisdiction of the patent
not pursued. 
 7.3 Obligation to Inform. BELLICUM agrees to keep BAYLOR reasonably informed, at [...***...]’s expense, of
prosecution and other actions pursuant to this Section 7, including submitting to BAYLOR copies of all official actions and responses thereto. 

7.4 Obligation to Cooperate. BAYLOR agrees to reasonably cooperate with BELLICUM to whatever extent is reasonably necessary to
provide BELLICUM the full benefit of the license granted herein. 
 7.5 Infringement Procedures. During the term of this
Agreement, each Party shall promptly inform the other of any suspected infringement of any claims in the Patent Rights or the misuse, misappropriation, theft or breach of confidence of other proprietary rights in the Subject Technology and/or Patent
Rights by a third party, and with respect to such activities as are suspected. Any action or proceeding against such third party shall be instituted as follows: 

(i) BAYLOR and BELLICUM may agree to jointly institute an action for infringement, misuse, misappropriation, theft or breach of confidence of
the proprietary rights against such third party. Such joint action shall be brought in the names of both BAYLOR and BELLICUM. If BAYLOR or BELLICUM decide to jointly prosecute an action or proceeding after it has been instituted by one Party, the
action shall be continued in the name or names they both agree is expedient for efficient prosecution of such action. BELLICUM and BAYLOR shall agree to the manner in which they shall exercise control over any joint action or proceeding, providing
however that if they cannot agree BAYLOR shall have the right to unilaterally decide on control. In such joint action or proceeding, the out-of-pocket costs shall be borne equally, and any recovery or settlement shall be shared equally. 

(ii) If BELLICUM does not agree to participate in a joint action or proceeding then BAYLOR shall have the right, but not the obligation, to
institute an action for infringement, misuse, misappropriation, theft or breach of confidence of the proprietary rights against such third party. If BAYLOR elects to institute action, it does so at its own cost. If BAYLOR fails to bring such an
action or proceeding within a period of three (3) months after receiving notice or otherwise having knowledge of such infringement, then BELLICUM shall have the right, but not the obligation, to prosecute the same at its own expense. Should
either BAYLOR or BELLICUM commence action under the provisions of this Paragraph 7.5 and 

  
 ***Confidential
Treatment Requested 
 - 6 - 

 
thereafter elect to abandon the same, it shall give timely notice to the other Party who may, if it so desires, continue prosecution of such action or proceeding. All recoveries, whether by
judgment, award, decree or settlement, from infringement or misuse of Subject Technology and/or Patent Rights shall be apportioned as follows: (a) the Party bringing the action or proceeding shall first recover an amount equal the costs and
expenses incurred by such Party directly related to the prosecution of such action or proceeding, (b) the Party cooperating in such action or proceeding shall then recover costs and expenses incurred by such Party directly related to its
cooperation in the prosecution of such action or proceeding and (c) the remainder will be divided proportionately between BAYLOR and BELLICUM according to the fraction of the costs and expenses incurred by each Party. 

7.6 Consent to Settle. Neither BAYLOR nor BELLICUM shall settle any action covered by Paragraph 7.5 without first obtaining the
consent of the other Party, which consent will not be unreasonably withheld. 
 7.7 Liability for Losses. BAYLOR shall not be
liable for any losses incurred as the result of an action for infringement brought against BELLICUM as the result of BELLICUM’s exercise of any right granted under this Agreement. The decision to defend or not defend shall be in BELLICUM’s
sole discretion. 
 8. TERM AND EXPIRATION 

Upon issuance of the Common Stock to Baylor as per the terms of Paragraph 3.1, BELLICUM shall have a perpetual, paid-in-full (i.e., royalty
free) license in and to the Subject Technology and Patent Rights. 
 9. TERMINATION 

9.1 Termination by Baylor: Breach. In the event of default or failure by BELLICUM to perform any of the terms, covenants or
provisions of this Agreement, BELLICUM shall have ninety (90) days after the receipt by BELLICUM of written notice of such default by BAYLOR to correct such default. If such default is not corrected within the said ninety (90) day period,
BAYLOR shall have the right, at its option, to cancel and terminate this Agreement. The Parties may mutually agree, in writing, to extend the cure period for a default if BELLICUM has demonstrated good faith efforts to cure said default. However,
BAYLOR is not obligated to grant such an extension. The failure of BAYLOR to exercise such right of termination shall not be deemed to be a waiver of any right BAYLOR might have, nor shall such failure preclude BAYLOR from exercising or enforcing
said right upon any subsequent failure by BELLICUM. 
 9.2 Termination by Baylor: Insolvency. BAYLOR shall have the right, at
its option, to cancel and terminate this Agreement in the event that BELLICUM shall (i) become involved in insolvency, dissolution, bankruptcy or receivership proceedings affecting the operation of its business or (ii) make an assignment
of all or substantially 

  
 - 7 - 

 
all of its assets for the benefit of creditors, or in the event that (iii) a receiver or trustee is appointed for BELLICUM and BELLICUM shall, after the expiration of thirty (30) days
following any of the events enumerated above, have been unable to secure a dismissal, stay or other suspension of such proceedings. 
 9.3
Termination by Bellicum. BELLICUM, upon thirty (30) days prior written notice to BAYLOR, may terminate this Agreement with or without cause. 

9.4 Effects of Termination. In the event of termination of this Agreement, all rights to the Subject Technology and Patent Rights
shall revert to BAYLOR. At the date of any termination of this Agreement, BELLICUM shall immediately cease using any of the Subject Technology and Patent Rights and BELLICUM shall immediately destroy the Subject Technology and send to BAYLOR a
written affirmation of such destruction signed by an officer of BELLICUM; provided, however, that BELLICUM may sell any Licensed Products actually in the possession of BELLICUM on the date of termination. 

9.5 Termination: Sublicenses. Upon termination of this Agreement by BELLICUM or BAYLOR, BAYLOR agrees to accept as a successor to
BELLICUM, any existing sublicense that is in compliance with the terms of this Agreement at the date of termination, provided however, that for each sublicense to be accepted the sublicensee agrees in writing to be bound to BAYLOR by the
provisions of this Agreement. The sublicensee for each sublicense to be accepted shall also agree that the license from BAYLOR to such sublicensee shall be adjusted to conform to the scope of the sublicense rights granted to the sublicensee by
BELLICUM. 
 9.6 No Refund. In the event this Agreement is terminated pursuant to this Section 9, BAYLOR is under no
obligation to refund any consideration made by BELLICUM to BAYLOR, as set forth in Section 3, prior to the effective date of such termination or expiration. 

9.7 Survival of Termination. No termination of this Agreement shall constitute a termination or a waiver of any rights of either
Party against the other Party accruing at or prior to the time of such termination. The obligations of Sections 12, 15 and 16 shall survive termination of this Agreement, 

10. ASSIGNABILITY 
 BELLICUM may
assign this Agreement as part of: 
 (i) A sale or other transfer of BELLICUM’s entire business; or 

(ii) A sale or other transfer of that part of BELLICUM’s business to which the license granted hereby relates; 

BELLICUM shall give BAYLOR [...***...] days prior written notice of such assignment, including the new contact information of assignee. BAYLOR, however, shall
not be 

  
 ***Confidential
Treatment Requested 
 - 8 - 

 
deemed to have approved such assignment and transfer unless and until such assignee has agreed in writing to BAYLOR to be bound by all the terms and provisions of this Agreement, in which event
BELLICUM shall be released of liability hereunder. Upon such assignment of this Agreement by such assignee, the term “ BELLICUM” as used herein (i) will include the name of the assignee should BELLICUM assign a partial right and/or
interest hereunder to the assignee, or (ii) will be replaced by the name of the assignee should BELLICUM assign its full right and interest hereunder to the assignee. 

11. GOVERNMENTAL COMPLIANCE 
 11.1
Compliance with Laws. BELLICUM shall, during the term of this Agreement and for so long as it shall use the Subject Technology or Patent Rights or sell Licensed Products, comply with and cause its sublicensees to comply with all laws
that may control the import, export, manufacture, use, sale, marketing, distribution and other commercial exploitation of the Subject Technology, Patent Rights, Licensed Products or any other activity undertaken pursuant to this Agreement. 

11.2 Export Control Regulations. The Subject Technology is subject to, and BELLICUM agrees to use commercially reasonable efforts
to comply with, U.S. law including but not limited to U.S. export controls under the Export Administration Regulations (15 C.F.R. Part 734 et seq.) and U.S. economic sanctions and embargoes codified in 31 C.F.R. Chapter V. BELLICUM agrees that
BELLICUM bears sole responsibility for understanding and complying with current U.S. trade controls laws and regulations as applicable to its activities subject to this Agreement. Without limitation on the general agreement to comply set forth in
the first sentence of this Paragraph 13.3, BELLICUM agrees not to sell any goods, services, or technologies subject to this Agreement, or to re-export the same: (1) to any destination prohibited by U.S. law, including any destination subject to
U.S. economic embargo; (2) to any end-user prohibited by U.S. law, including any person or entity listed on the U.S. government’s Specially Designated Nationals list, Denied Parties List, Debarred Persons List, Unverified List, or Entities
List. Furthermore, any transfer of Patent Rights from BAYLOR to BELLICUM under this Agreement may be subject to U.S. export license authorization under U.S. law, and BAYLOR agrees to comply with applicable laws for such transfer. 

11.3 Requirement for U.S. Manufacture. BAYLOR represents and certifies that research giving rise to the Patent Rights was funded
by Federal funds, and that such Federal funds were solely from the National Institutes of Health (NIH) and the Department of Defense (DOD). BELLICUM agrees that Licensed Products developed as a result of such Federal funds and are leased or sold in
the United States shall be manufactured substantially in the United States, unless a written waiver is obtained from the NIH and/or the DOD. At the request of BELLICUM, BAYLOR agrees to the best of its abilities to assist BELLICUM should BELLICUM
seek such a waiver. 

  
 - 9 - 

 12. ARBITRATION  

12.1 Amicable Resolution. The Parties shall attempt to settle any controversy between them amicably. To this end, a senior
executive from each Party shall consult and negotiate to reach a solution. The Parties agree that the period of amicable resolution shall toll any otherwise applicable statute of limitations. However, nothing in this clause shall preclude any Party
from commencing mediation if said negotiations do not result in a signed written settlement agreement within [...***...] days after written notice that these amicable resolution negotiations have commenced. 

12.2 Mediation. If a controversy arises out of or relates to this agreement, or the breach thereof, and if the controversy cannot
be settled through amicable resolution, the Parties agree to try in good faith to settle the controversy by mediation before resorting to final and binding arbitration. The Party seeking mediation shall propose five mediators, each of whom shall be
a lawyer licensed to practice by the state of Texas, having practiced actively in the field of commercial law for at least 15 years, to the other Party who shall select the mediator from the list. The Parties shall split the cost of the mediator
equally. The Parties agree that the period of mediation shall toll any otherwise applicable statute of limitations. However, nothing in this clause shall preclude any Party from commencing arbitration if said negotiations do not result in a signed
written settlement agreement within [...***...] days after written notice that amicable resolution negotiations have commenced, 
 12.3
Arbitration. Any dispute, controversy, or claim arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, including claims for tortious interference or other tortious or statutory claims arising
before, during or after termination, providing only that such claim touches upon matters covered by this Agreement shall be finally settled by arbitration administered by the American Arbitration Association pursuant to the Commercial Arbitration
Rules in force at the time of the commencement of the arbitration, except as modified by the specific provisions of this Agreement. It is the specific intent of the Parties that this arbitration provision is intended to be the broadest form allowed
by law. 
 12.4 Parties to Arbitration. This agreement to arbitrate is intended to be binding upon the signatories hereto,
their principals, successors, assigns, subsidiaries and affiliates. This agreement to arbitrate is also intended to include any disputes, controversy or claims against any Party’s employees, agents, representatives, or outside legal counsel
arising out of or relating to matters covered by this Agreement or any agreement in which this Agreement is incorporated. 
 12.5
Consolidation Permitted. The Parties expressly agree that any court with jurisdiction may order the consolidation of any arbitrable controversy under this Agreement with any related arbitrable controversy not arising under this
Agreement, as the court may deem necessary in the interests of justice or efficiency or on such other grounds as the court may deem appropriate. 

12.6 Entry of Judgment. The Parties agree that a final judgment on the arbitration award may be entered by any court having
jurisdiction thereof. 

  
 ***Confidential
Treatment Requested 
 - 10 - 

 12.7 Appointing Arbitrators. The American Arbitration Association shall appoint the
arbitrator(s) from its Large, Complex Claims Panel. If such appointment cannot be made from the Large, Complex Claims Panel, then from its Commercial Panel. The Parties hereby agree to and acquiesce in any appointment of an arbitrator or arbitrators
that may be made by such appointing authority. 
 12.8 Qualifications of the Arbitrator(s). The arbitrator(s) must be a lawyer,
having practiced actively in the field of commercial law for at least 15 years. 
 12.9 Governing Substantive Law. The
arbitrator(s) shall determine the rights and obligations of the Parties according to the substantive laws of the State of Texas (excluding conflicts of law principles) as though acting as a court of the State of Texas. 

12.10 Governing Arbitration Law. The law applicable to the validity of the arbitration clause, the conduct of the arbitration,
including any resort to a court for provisional remedies, the enforcement of any award and any other question of arbitration law or procedure shall be the Federal Arbitration Act. 

12.11 Governing Convention. The Parties elect to have the New York Convention on the Recognition and Enforcement of Foreign
Arbitral Awards of June 10, 1958 (instead of the inter-American New York Convention on international Commercial Arbitration of August 15, 1990) govern any and all disputes that may be the subject of arbitration pursuant to this Agreement.

 12.12 Preliminary Issues of Law. The arbitrator(s) shall hear and determine any preliminary issue of law asserted by a Party
to be dispositive of any claim, in whole or part, in the manner of a court hearing a motion to dismiss for failure to state a claim or for summary judgment, pursuant to such terms and procedures as the arbitrator(s) deems appropriate. 

12.13 Confidentiality. The Parties and the arbitrator(s) shall treat all aspects of the arbitration proceedings, including
without limitation discovery, testimony and other evidence, briefs and the award, as strictly confidential. Further, except as may be required by law, neither Party nor the arbitrator(s) may disclose the existence, content, or results of any
arbitration hereunder without the prior written consent of both Parties. 
 12.14 Place of Arbitration. The seat of arbitration
shall be Houston, Texas, USA. 
 12.15 Language. The arbitration shall be conducted in the English language. All submissions
shall be made in English or with an English translation. Witnesses may provide testimony in a language other than English, provided that a simultaneous English translation is provided. Each Party shall bear its own translation costs. 

  
 - 11 - 

 12.16 Punitive Damages Prohibited. The Parties hereby waive any claim to any
damages in the nature of punitive, exemplary, or statutory damages in excess of compensatory damages, or any form of damages in excess of compensatory damages, and the arbitrator(s) is/are specially divested of any power to award any damages in the
nature of punitive, exemplary, or statutory damages in excess of compensatory damages, or any form of damages in excess of compensatory damages. 

12.17 Costs. The Party prevailing on substantially all of its claims shall be entitled to recover its costs, including
attorneys’ fees, for the arbitration proceedings, as well as for any ancillary proceeding, including a proceeding to compel or enjoin arbitration, to request interim measures or to confirm or set aside an award. 

12.18 Survival. The provisions of this Section 12 shall survive expiration or termination of this Agreement 

13. ADDRESSES 
 13.1 Baylor
Payment Address. All certificates of common stock shall be sent to the address below, and shall reference the applicable OTA numbers listed on the front page of the Agreement. 

BAYLOR Tax ID #: 74-1613878 

Director, Baylor Licensing Group 

Baylor College of Medicine 
 One
Baylor Plaza, BCM210-600D 
 Houston, TX 77030 
  

							
		 	Telephone No.	  	713-798-6821	  	
		 	Facsimile No.	  	713-798-1252	  	
		 	E-Mail	  	blg@bcm.tmc.edu	  	

 13.2 Bellicum Contact Address. For questions about stock certificates, BAYLOR can contact
BELLICUM at the address below: 
 Thomas J. Farrell, CEO 

Bellicum Pharmaceuticals, Inc. 

Twelve Greenway Plaza, Suite 1380 

Houston, TX 77046 
  

							
		 	Telephone No.	  	(512) 542-0010	  	
		 	Facsimile No.	  	(512) 542-0062	  	
		 	E-Mail: tfarrell@bellicum.com	  	

  
 - 12 - 

 13.3 Address for Notices. All notices, reports or other communication pursuant to
this Agreement shall be sent to such Party via (i) United States Postal Service postage prepaid, (ii) overnight courier, or (iii) facsimile transmission, addressed 

to it at its address set forth below or as it shall designate by written notice given to the other Party. Notice shall be sufficiently made, or given and
received (a) on the date of mailing or (b) when a facsimile printer reflects transmission. 
 In the case of BAYLOR: 

Patrick Turley 
 Associate General
Counsel 
 Baylor College of Medicine 

One Baylor Plaza, BCM210-600D 

Houston, TX 77030 
  

							
		  	Telephone No.	  	713-798-6821	  	
		  	Facsimile No.	  	713-798-1252	  	
		  	E-Mail	  	blg@bcm,tmc.edu	  	

 In the case of BELLICUM: 

Thomas J. Farrell, CEO 
 Bellicum
Pharmaceuticals, Inc. 
 Twelve Greenway Plaza, Suite 1380 

Houston, TX 77046 
  

							
		 	Telephone No.	  	(512) 542-0010	  	
		 	Facsimile No.	  	(512) 542-0062	  	
		 	E-Mail:	  	tfarrell@bellicum.com	  	

 14.4 Baylor Reference Number. Each such report, notice or other communication shall include the
applicable Baylor reference numbers listed on the front page of the Agreement. 
 15. REPRESENTATIONS, INDEMNITY & INSURANCE  

15.1 BELLICUM Representations. BELLICUM hereby represents and certifies that: 

(i) it is a corporation duly organized and in good standing under the laws of the State of Delaware; 

(ii) it is qualified to do business and in good standing in the State of Texas and elsewhere as the nature of its business and properties so
require; 
 (iii) the execution, delivery and performance of this Agreement by BELLICUM and the consideration provided for herein has been
duly authorized by corporate action; 
 (iv) it has the full power and authority to enter into and carry out its obligations under this
Agreement; and 

  
 - 13 - 

 (v) the Common Stock to be issued pursuant to this Agreement has been duly authorized and upon
issuance, pursuant to the terms hereof and for the consideration herein set forth, will be validly issued, fully paid and non-assessable. 
 BELLICUM agrees
to indemnify and hold BAYLOR and its officers, trustees, faculty, employees, agents and representatives, harmless from any liabilities, costs and expenses (including attorneys’ fees and expenses), obligations or causes of action arising out of
or related to any breach of the representations and certifications made by BELLICUM in this Section 15.1. 
 15.2 BAYLOR
Representations. BAYLOR represents and certifies it controls the entire right, title and interest in the Patent Rights and the Subject Technology BAYLOR owns and is fully authorized to make the grant in Section 2.1 of the Agreement. 

15.3 GENERAL INDEMNITY. 

(I) EACH PARTY SHALL NOTIFY THE OTHER OF ANY CLAIM, LAWSUIT OR OTHER PROCEEDING RELATED TO THE SUBJECT TECHNOLOGY AND PATENT RIGHTS.
BELLICUM AGREES THAT IT WILL DEFEND, INDEMNIFY AND HOLD HARMLESS BAYLOR, ITS FACULTY MEMBERS, SCIENTISTS, RESEARCHERS, EMPLOYEES, OFFICERS, TRUSTEES AND AGENTS AND EACH OF THEM (THE “INDEMNIFIED PARTIES”), FROM AND AGAINST ANY AND ALL
CLAIMS, CAUSES OF ACTION, LAWSUITS OR OTHER PROCEEDINGS (THE “BAYLOR CLAIMS”) FILED OR OTHERWISE INSTITUTED AGAINST ANY OF THE INDEMNIFIED PARTIES ARISING OUT OF THE DESIGN, PROCESS, MANUFACTURE OR USE BY BELLICUM OF THE SUBJECT
TECHNOLOGY, PATENT RIGHTS, OR LICENSED PRODUCTS; PROVIDED, HOWEVER, THAT SUCH INDEMNITY SHALL NOT APPLY TO ANY CLAIMS ARISING FROM THE NEGLIGENCE OR INTENTIONAL MISCONDUCT OF ANY INDEMNIFIED PARTY. BELLICUM WILL ALSO ASSUME RESPONSIBILITY FOR ALL
COSTS AND EXPENSES RELATED TO SUCH CLAIMS FOR WHICH IT IS OBLIGATED TO INDEMNIFY THE INDEMNIFIED PARTIES PURSUANT TO THIS PARAGRAPH 15.3, INCLUDING, BUT NOT LIMITED TO, THE PAYMENT OF ALL REASONABLE ATTORNEYS’ FEES AND COSTS OF LITIGATION OR
OTHER DEFENSE. 
 (II) BELLICUM FURTHER AGREES NOT TO SETTLE ANY CLAIM AGAINST A BAYLOR INDEMNITEE WITHOUT THE INDEMNITEE’S
WRITTEN CONSENT WHICH CONSENT SHALL NOT BE UNREASONABLY WITHHELD. BELLICUM FURTHER AGREES TO KEEP BAYLOR INDEMNITEES FULLY APPRISED OF THE BAYLOR CLAIMS. 

  
 - 14 - 

 15.4 Insurance. 

(i) BELLICUM shall, for so long as BELLICUM manufactures, uses or sells any Licensed Product(s) for research applications, maintain in full force and effect
policies of (a) general liability insurance with limits of not less than [...***...] dollars ($[...***...]) per occurrence with an annual aggregate of [...***...] dollars ($[...***...]) and (b) products liability insurance, with limits of
not less than [...***...] dollars ($[...***...]) per occurrence with an annual aggregate of [...***...] dollars ($[...***...]). 
 (ii) BELLICUM shall
provide to BAYLOR copies of certificates of insurance or copies of the policies of insurance within [...***...] days after BELLICUM receives a request from BAYLOR for such copies. It is the intention of the Parties hereto that BELLICUM shall,
throughout the term of this Agreement, continuously and without interruption, maintain in force the required insurance coverages set forth in this Paragraph 15.4. 

(iii) BAYLOR reserves the right to request additional policies of insurance where appropriate and reasonable in light of BELLICUM’s business operations
and availability of coverage. 
 15.5 DISCLAIMER OF WARRANTY. BAYLOR MAKES NO WARRANTIES OR REPRESENTATIONS OTHER THAN THOSE MADE
ABOVE, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF FITNESS OR MERCHANTABILITY, REGARDING OR WITH RESPECT TO THE SUBJECT TECHNOLOGY, PATENT RIGHTS OR LICENSED PRODUCTS AND BAYLOR MAKES NO WARRANTIES OR REPRESENTATIONS, EXPRESS OR
IMPLIED, OF THE PATENTABILITY OF THE SUBJECT TECHNOLOGY, PATENT RIGHTS OR LICENSED PRODUCTS OR OF THE ENFORCEABILITY OF ANY PATENTS ISSUING THEREUPON, IF ANY, OR THAT THE SUBJECT TECHNOLOGY, PATENT RIGHTS OR LICENSED PRODUCTS ARE OR SHALL BE FREE
FROM INFRINGEMENT OF ANY PATENT OR OTHER RIGHTS OF THIRD PARTIES. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS UNDER ANY PATENTS OF BAYLOR OTHER THAN THE PATENT RIGHTS,
REGARDLESS OF WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS.  
 16. ADDITIONAL PROVISIONS 

16.1 Use of BAYLOR Name. BAYLOR agrees that BELLICUM may publicly disclose the existence of this Agreement, the name “Baylor
College of Medicine” and the names of scientists and researchers at BAYLOR associated with the Patent Rights and Technology Rights. BELLICUM will not disclose it has an affiliation with BAYLOR that does not exist at the time the name
“Baylor College of Medicine” is publicly disclosed. 

  
 ***Confidential
Treatment Requested 
 - 15 - 

 16.2 Confidentiality. 

(i) Confidential Information will be marked “CONFIDENTIAL.” The recipient of Confidential Information (“Recipient”) agrees to retain in
confidence and to prevent the disclosure of the Confidential Information from the discloser (“Discloser”) to any third party without the prior written consent of the Discloser; provided, however, the Recipient may disclose Confidential
Information to its officers, directors, employees, partners, investors, shareholders, lawyers, accountants, and consultants (collectively, the “Representatives”) on a need-to-know basis only for the purpose of assisting the Recipient in
evaluating the Confidential Information or in the discharge of its obligations under this Agreement. The Recipient will use the same degree of care with respect to the Confidential Information as it would with its own proprietary and confidential
information, and in no event use less than a reasonable degree of care. The Recipient will use reasonable efforts to notify its Representatives about the Recipient’s duties under this Agreement and to promote Representatives’ maintenance
of the confidentiality of the Confidential Information as if the Representatives were themselves parties to this Agreement. BELLICUM may disclose Confidential Information to potential licensees, purchasers, investors, joint venturers and the like so
long as BELLICUM uses commercially reasonable efforts to make such disclosures subject to a confidentiality agreement. The Recipient agrees to retain in confidence and to prevent the disclosure of any document prepared by or for the Recipient that
includes Discloser’s Confidential Information, including without limitation any document that analyzes or summarizes Discloser’s Confidential Information, to any third party without the prior written consent of the Discloser. 

(ii) This Agreement imposes no obligations upon the Recipient with respect to any Confidential Information which (a) was in the Recipient’s
possession before receipt of such information from the Discloser, as evidenced by competent written proof; (b) is or becomes a matter of public knowledge through no fault or violation of this Agreement by the Recipient or its Representatives;
(c) is rightfully received by the Recipient from a third party who, to the Recipient’s knowledge, is not under a duty of confidentiality; (d) is approved in writing for release by the Discloser prior to such release; (e) is
independently developed by the Recipient as evidenced by Recipient’s written records without any use of or reference to Confidential Information of the Discloser; or (f) is orally disclosed and not confirmed in a writing to the Recipient
within thirty (30) days after its initial disclosure by the Discloser. Notwithstanding any other provision of this Agreement, the Recipient may disclose Confidential Information which is required to be disclosed by law, rule, regulation,
administrative, or legal process (“Compelled Request”); provided, however, the Recipient will give prompt written notice of any Compelled Request for such information to the Discloser and agrees to cooperate with the Discloser, at the
Discloser’s expense, to challenge the request or limit the scope of disclosure of such information, as the Discloser may request and deem appropriate. 

(iii) Each Party agrees to notify the other Party in writing of any misuse or misappropriation of the other Party’s Confidential Information that may come
to its attention. The Parties hereby acknowledge and agree that in the event of any breach of this Section 16.2, including, without limitation, the actual or threatened disclosure or unauthorized use of Confidential Information without the
prior express written consent of the Discloser, the Discloser would suffer an irreparable injury such that no remedy at law would adequately protect or appropriately compensate the disclosing party for such

  
 - 16 - 

 
injury. Accordingly, the Parties agree that the Discloser will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief,
without bond and without prejudice to any other rights and remedies that the Discloser may have for a breach of this Section 16.2. 

16.3 No Additional Rights. BELLICUM acknowledges that, other than the specific rights granted hereunder, it is not entitled to
any rights to any current or future technology, research or developments made at or owned by BAYLOR, 
 16.4 BAYLOR’s
Disclaimers. Neither BAYLOR, nor any of its faculty members, scientists, researchers, employees, officers, trustees or agents assume any responsibility for the manufacture, product specifications, sale or use of the Subject Technology or the
Licensed Products which are manufactured by or sold by BELLICUM. 
 16.5 Independent Contractors. The Parties hereby
acknowledge and agree that each is an independent contractor and that neither Party shall be considered to be the agent, representative, master or servant of the other Party for any purpose whatsoever, and that neither Party has any authority to
enter into a contract, to assume any obligation or to give warranties or representations on behalf of the other Party. Nothing in this relationship shall be construed to create a relationship of joint venture, partnership, fiduciary or other similar
relationship between the Parties. 
 16.6 Non-Waiver. The Parties covenant and agree that if a Party fails or neglects for any
reason to take advantage of any of the terms provided for the termination of this Agreement or if a Party, having the right to declare this Agreement terminated, shall fail to do so, any such failure or neglect by such Party shall not be a waiver or
be deemed or be construed to be a waiver of any cause for the termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants or conditions of this Agreement or of the performance thereof. None of the terms,
covenants and conditions of this Agreement may be waived by a Party except by its written consent. 
 16.7 Reformation. The
Parties hereby agree that neither Party intends to violate any public policy, statutory or common law, rule, regulation, treaty or decision of any government agency or executive body thereof of any country or community or association of countries,
and that if any word, sentence, paragraph or clause or combination thereof of this Agreement is found, by a court or executive body with judicial powers having jurisdiction over this Agreement or any of the Parties hereto, in a final, unappealable
order to be in violation of any such provision in any country or community or association of countries, such words, sentences, paragraphs or clauses or combination shall be inoperative in such country or community or association of countries, and
the remainder of this Agreement shall remain binding upon the Parties hereto. 

  
 - 17 - 

 16.8 Force Majeure. No liability hereunder shall result to a Party by reason of
delay in performance caused by force majeure, that is circumstances beyond the reasonable control of the Party, including, without limitation, acts of God, fire, flood, war, terrorism, civil unrest, labor unrest, or shortage of or inability to
obtain material or equipment. 
 16.9 Informed Review. Each Party acknowledges that it and its counsel have received and
reviewed this Agreement and that normal rules of construction, to the effect that ambiguities are to be resolved against the drafting Party, shall not apply to this Agreement or to any amendments, modifications, exhibits or attachments to this
Agreement. 
 16.10 Entire Agreement. The terms and conditions herein constitute the entire agreement between the Parties and
shall supersede all previous agreements, either oral or written, between the Parties hereto with respect to the subject matter hereof. No agreement of understanding bearing on this Agreement shall be binding upon either Party hereto unless it shall
be in writing and signed by the duly authorized officer or representative of each of the Parties and shall expressly refer to this Agreement. 

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple originals by their duly authorized officers and
representatives on the respective dates shown below, but effective as of the Agreement Date. 
  

									
	BELLICUM PHARMACEUTICALS, INC.	  		  	BAYLOR COLLEGE OF MEDICINE
					
	Name:	  	 /s/ Thomas J. Farrell
	  		  	Name:	  	 /s/ Cyndi M. Bailey

		  	Thomas J. Farrell	  		  		  	Cyndi M. Bailey
	Title:	  	Chief Executive Officer	  		  	Title:	  	Senior Vice President & General Counsel
			
	Date: 3/20/08	  		  	Date: 3/8/08

  
 - 18 - 

 Appendix A 

Subject Technology Supplied by Baylor to Bellicum: 

  
 - 19 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]